Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix

BMC Cancer

Gang Chen²  Cheng He²  Ling Li¹  An Lin¹  Xiongwei Zheng²  Ellen He³  Sven Skog³ 

[1] Department of Pathology, Fujian Provincial Cancer Hospital, Teaching 472 Hospital of Fujian Medical University, Fuzhou, Fujian, 350014, China

[2] Department of Pathology, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian, 350014, China

[3] Sino-Swed Molecular Bio-Medicine Research Institute, No. 2–304 Bio-tech Industry Incubator, High-tech Industrial Park, Gaoxin, C. Ave. 1st, Shenzhen, PC. 518057, China

关键词: Ki-67;    TK1;    Invasive cervical carcinoma;    Cervical intraepithelial neoplasia (CIN);    Cervical lesions;   

Others  :  1079742
DOI  :  10.1186/1471-2407-13-249

 received in 2012-05-17, accepted in 2013-05-14,  发布年份 2013

【 摘 要 】

Background

Thymidine kinase 1 (TK1) is a proliferation biomarker that has been found useful for prognostication in cancer patients. Here we investigate for the first time the use of TK1 expression as a prognostic factor for patients with premalignant and malignant lesions of the uterine cervix.

Methods

TK1 expression was determined by immunohistochemistry in cervical lesions (cervical intraepithelial neoplasia (CIN), n = 216; invasive cervical carcinoma, n = 84). TK1 and Ki-67 expressions and pathological/FIGO stages and age were correlated with 5-year survival by Kaplan-Meier, log rank and COX hazard uni- and multivariate analyses.

Results

TK1 labeling index (LI) was significantly correlated with CIN grades and invasive cervical carcinoma stages, while TK1 labeling intensity was only correlated to CIN grades. TK1 LI was significantly higher compared with Ki-67 LI. TK1 LI correlated significantly to 5-year survival in patients with invasive cervical carcinoma, particularly nuclear TK1 LI. In a multivariate analysis, nuclear TK1 expression was independent prognostic factor in patients with in situ/invasive cervical carcinoma or in invasive cervical carcinoma alone. Interestingly, in invasive cervical carcinoma patients with advanced tumors, nuclear TK1 expression could identify patients with significantly better survival rates (80%), while Ki-67 could not.

Conclusions

Nuclear TK1 expression in early grade CIN predicts risk for progression to malignancy. Nuclear TK1 expression is also a prognostic factor for treatment outcome, particularly in patients with advanced cervical carcinomas. Nuclear TK1 expression is more useful than Ki-67 and pathological/FIGO stages.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Imesch P, Fink D: Cervical cancer Ther Umsch. 2011, 68:545-552.
• [2]Cheung FY, Mang OW, Law SC: A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong 1997–2006. Hong Kong Med J 2011, 17:89-95.
• [3]Underwood JCE: General and systematic pathology. London: Churchill Livingstone; 2005.
• [4]Kovács K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pajor L, Bollmann R, Hildenbrand R: A 7.5-year prospective study of longer than 18 months type-specific human papillomavirus persistence in a routine cytology-based cervical screening population of about 31,000 women in West Germany. Eur J Cancer Prev 2009, 18:307-315.
• [5]Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ: Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13:78-88.
• [6]Isacson C, Kessis TD, Hedrick L, Cho KR: Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996, 56:669-674.
• [7]Kruse AJ, Baak JP, Janssen EA, Kjellevold KH, Fiane B, Lovslett K, Bergh J, Robboy S: Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 2004, 26:13-20.
• [8]Queiroz C, Silva TC, Alves VA, Villa LL, Costa MC, Travassos AG, Filho JB, Studart E, Cheto T, de Freitas LA: Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. Pathol Res Pract 2006, 202:731-737.
• [9]Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, Lee DW, Kim SW, Kim JH, Kim YT, Kim S, Kim JW: Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol 2008, 19:162-168.
• [10]Gertych A, Joseph AO, Walts AE, Bose S: Automated detection of dual p16/Ki67 nuclear immunoreactivity in liquid-based pap tests for improved cervical cancer risk stratification. Ann Biomed Eng 2012, 40:1192-1204.
• [11]Gasparri F, Wang N, Skog S, Galvani A, Eriksson S: Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. Eur J Cell Biol 2009, 88:779-785.
• [12]Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J, He E, Eriksson S, Wen W, Skog S: Thymidine kinase 1 expression is significantly different in breast benign (UDH), and in pre-malignant (ADH), primary tumour in situ (DCIS) and invasive ductal (IDC) of breast carcinoma. Mol Med Rep 2009, 2:923-929.
• [13]Ye FP, Xie QL, Liu XL, Zeng JH, Nan JL, Yu M: Expression of TK1 and Ki67 in prostate diseases. J Clin Exp Pathol 2008, 24:644-667.
• [14]Aufderklamm S, Hennenlotter J, Todenhoefer T, Gakis G, Schilling D, Vogel U, Kuehs U, Dlugosch J, Knapp J, Merseburger A, Gerber V, Ordelheide A, Hevler J, Stenzl A, Schwentner C: XPA-210: a new proliferation marker determines locally dvanced prostate cancer and is a predictor of biochemical recurrence. World J Urol 2011, 4:21969130. PMID
• [15]Liu C, Gao Q, Shi QL, Yu B, Ma HH, Eriksson S, He E, Skog S: Significance of TK1 and Ki-67 expression in ovarian serous adenocarcinoma. J Clin Exp Pathol 2011, 27:1289-1293.
• [16]Kruck S, Hennenlotter J, Vogel U, Schilling D, Gakis G, Hevler J, Kuehs U, Stenzl A, Schwentner C: Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications. BJU Int 2012, 109:634-638.
• [17]Xu Y, Shi QL, Ma H, Zhou H, Lu Z, Yu B, Zhou X, Eriksson S, He E, Skog S: High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma. Tumor Biol 2012, 33:475-483.
• [18]Gakis G, Hennenlotter J, Scharpf M, Hevler J, Schilling D, Kuehs U, Stenzl A, Schwentner C: XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma. World J Urol 2011, 29:801-806.
• [19]Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A, Schwentner C: Thymidine kinase and cancer monitoring. Cancer Lett 2012, 6:6-10.
• [20]Topolcan O, Holubec L Jr: The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn 2008, 2:129-141.
• [21]He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, Tang LL, Hu GZ, Li Y, Zhang M, Zhou J, Eriksson S, Fornander T, Skog S: Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleosides Nucleotides Nucleic Acids 2010, 29:352-358.
• [22]Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000, 70:209-262.
• [23]Sobin LH, Wittekind C: International Union against Cancer (UICC) TNM Classification of Malignant Tumours 6th edition. New Jersey: John Wiley & Sons; 2002.
• [24]He Q, Wang N, Skog S, Ericsson S, Tribukait B: Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Europ J Cell Biol 1996, 70:117-124.
• [25]Chen YL, Eriksson S, Chang ZF: Regulation and functional contribution thymidine kinase 1 in repair of DNA damage. J Biol Chem 2010, 285:27327-27335.